Olipudase alfa (Xenpozyme®) is a recombinant human ASM enzyme replacement therapy (ERT) approved for the treatment of the non-central nervous system manifestations of ASMD in children and adults. Here, SMPD1 is linked to anterior segment dysgenesis.